NanoViricides Raises $20 Million in a Registered Direct Offering
NanoViricides, Inc. has raised approximately $20 million in a registered direct offering. The company will receive approximately $18.8 million in proceeds after deducting approximately $1.2 million for broker commissions and attorney fees.
"We were very pleased with the strong interest from select institutional investors and existing shareholders," said Eugene Seymour, MD, MPH, CEO of the company. He added: "It enabled us to raise $20 million in place of the intended $10 milion, taking advantage of the 20% additional allowance option for our registered securities."
Dr Seymour further explained: "We anticipate that the additional capital will be sufficient to last through Phase I and II human clinical studies of our injectable FluCide drug candidate, and through initial human clinical trials of DengueCide." DengueCide has received Orphan Drug designation by the US FDA as well as the European Medical Agency (EMA). These designations entail significant benefits, allowing the company to prioritise development of DengueCide.
With this raise, the company now has approximately $40 million cash in hand (including non-current cash-based assets), which the company believes is sufficient for its planned activities for the next 3 years and beyond. With these funds, in addition to certain clinical trials for FluCide and DengueCide, the company anticipates that it will also be able to expedite development of its four other drug candidates, namely, Oral FluCide, HerpeCide, HIVCide, and EKCCide into the FDA approval process.
With this additional capital, the company anticipates being able to hire necessary staff to accommodate the expanded workload as it gears several of its drug candidates towards IND filings over the near future. Further, the company will be able to continue its R&D programmes, such as nanoviricides against Rabies and Ebola/Marburg viruses. The company believes it will also be able to pursue additional R&D programmes such as developing nanoviricides against the recently discovered Middle East Respiratory Syndrome (MERS) virus (a Coronavirus), as well as other opportunities. These programmes should result in additional drug candidates in the company's already robust pipeline in the near future.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance